Treatment for glioblastoma (GBM)
Intended for US audiences only.
Optune® Novocure™

Patient educational materials

The following are educational materials about Optune, which you can review with your patients to introduce them to Optune. The timeline below indicates which educational materials are appropriate for patients at each time point in their journey with GBM.

At Diagnosis

First Glance at Optune
Provide this piece to patients as a simple overview of Optune.
View this PDF

Treatment Consideration

Patient MOA video
The Patient MOA Video, or “TTFields Chalk Talk”, is a resource to educate patients and caregivers on the way Optune works. The video uses patient-friendly language and graphics to help explain TTFields and their effect on GBM tumor cells.
View this video
Understanding Optune - Educational Resource for HCPs
This tool is designed to aid in your discussions with patients who are considering Optune. It contains patient-friendly infographics to help you explain the details of Optune treatment, including the MOA, efficacy, safety, and side effects.
View this PDF
Understanding Optune - Take home guide for patients/caregivers
After discussing Optune, this piece can be provided to patients to remind them of the topics you discussed face-to-face.
View this PDF
Buddy Program
Optune Ambassadors are GBM patients and caregivers who are willing to share their personal experiences integrating Optune into everyday life, as well as their personal interactions with nCompass support services. Ambassadors are trained to participate in Buddy Program calls. Buddy calls are arranged phone conversations between Ambassadors and GBM patients/caregivers who:
1) Are considering Optune
2) Are about to start Optune
3) Have recently started Optune
View this PDF
nCompass Patient Brochure
Provide your patients and caregivers with this brochure to explain the kind of support they can expect during their Optune treatment.
View this PDF

Compliance and Self-Management

Patient Scalp Care Guidelines
This educational guide can be provided to Optune patients who have questions about scalp care and transducer array placement.
View this PDF
Patient Travel Support by nCompass™ brochure
Provide to patients and caregivers who plan to travel while on Optune. It includes answers to frequently asked travel questions and provides checklists of what to pack and bring with them when traveling.
View this PDF
Optune Insights
Provide patients and caregivers this supportive material that gives the perspective of an Optune patient and her caregiver regarding their experience with Optune.
View this PDF

How Optune works

See how Tumor Treating Fields (TTFields) disrupt mitosis and inhibit tumor growth.

Watch video

Review the results

Learn more about the efficacy results in newly diagnosed GBM.

See the data

OPT-055.5-20


Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).

Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy.

For the treatment of recurrent GBM, Optune is indicated following histologically-or radiologically-confirmed recurrence in the supratentorial region of the brain after receiving chemotherapy. The device is intended to be used as a monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.

Important Safety Information

Contraindications

Do not use Optune in patients with an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with implanted electronic devices has not been tested and may theoretically lead to malfunctioning of the implanted device. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective.

Do not use Optune in patients that are known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions such as shock and respiratory failure.

Warnings and Precautions

Optune can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure (the device manufacturer).

Do not prescribe Optune for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune in these populations have not been established.

The most common (≥10%) adverse events involving Optune in combination with temozolomide were thrombocytopenia, nausea, constipation, vomiting, fatigue, medical device site reaction, headache, convulsions, and depression.

The most common (≥10%) adverse events seen with Optune monotherapy were medical device site reaction and headache.

The following adverse reactions were considered related to Optune when used as monotherapy: medical device site reaction, headache, malaise, muscle twitching, fall and skin ulcer.

Use of Optune in patients with an inactive implanted medical device in the brain has not been studied for safety and effectiveness, and use of Optune in these patients could lead to tissue damage or lower the chance of Optune being effective.

If the patient has an underlying serious skin condition on the scalp, evaluate whether this may prevent or temporarily interfere with Optune treatment.


Please click here to see the Optune Instructions For Use (IFU) for complete information regarding the device's indications, contraindications, warnings, and precautions.

Patient Journey videos on this site depict actual patients and caregivers. All other depictions of patients, caregivers and health care professionals are actor portrayals.

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).